Xiaowei Shi

Xiaowei Shi

Auto-generated profile, based on publicly available information

Xiaowei Shi

Chu Kochen Honors College, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
JWJian Wu
Jian Wu
WLWei Li
Wei Li
XSXiaowei Shi
Xiaowei Shi
ZCZhongming Chen
Zhongming Chen
BJBin Jiang
Bin Jiang
LLLanjuan Li
Lanjuan Li

21 March 2018 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
LZLu Zhao
Lu Zhao
SCshanquan chen
shanquan chen
XSXiaowei Shi
Xiaowei Shi
Hongcui CaoHongcui Cao
Hongcui Cao
LLLanjuan Li
Lanjuan Li
Liver disease is a major cause of death and disability. Mesenchymal stem cells (MSCs) show promise for the treatment of liver disease. However, whether MSC-based therapy is more effective than conventional treatment is unclear, as are the optimal MSC source, the administration frequency, and the most effective MSC delivery route. We therefore undertook a systematic review and meta-analysis of the therapeutic efficacy of MSCs against liver disease and the related factors. We systematically searched Medline (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM to identify studies published up to June 2017 involving liver disease patients receiving MSC-based therapy and which reported estimates of liver function during the follow-up period. Thirty-nine studies were selected from 672 publications. According to a meta-analysis of 23 controlled studies, compared with conventional treatment MSC therapy significantly improves liver function in patients with liver disease in terms of the model of end-stage liver disease score, albumin, alanine aminotransferase, and total bilirubin levels, and prothrombin time, up to 6 months after administration. However, it has no beneficial effects in terms of prothrombin activity, international normalized ratio, or cholinesterase level. Considerable heterogeneity was identified at most time points. Subgroup analyses showed that a single MSC injection was more effective than multiple injections, MSC administration was more effective via the hepatic artery than the peripheral vein, and MSCs derived from bone marrow were more effective than those derived from the umbilical cord. MSC-based therapy is relatively safe and improves liver function during the first 6 months after administration. A single injection administration via the hepatic artery and MSCs derived from bone marrow are optimal in terms of improving liver function. However the significant heterogeneity among studies and discontinuous results of the subgroup meta-analysis should be addressed; moreover the long-term efficacy of MSC therapy warrants further investigation.

23 August 2019 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
JLJingqi Liu
Jingqi Liu
BFBing Feng
Bing Feng
YXYanping Xu
Yanping Xu
JZJiaqi Zhu
Jiaqi Zhu
XFXudong Feng
Xudong Feng
LLLanjuan Li
Lanjuan Li
The efficacy of mesenchymal stem cell (MSC)-based therapy for acute liver injury (ALI) involves coordination with the hepatic immune system, a complex and coordinated network of immune-cell interactions. However, studies of the immunomodulatory effects of MSCs have focused on a limited number of cell subsets rather than a systematic assessment. Carbon tetrachloride (CCl4) was used to induce ALI in mice. To determine the efficacy of MSCs, ALI mice were injected with MSCs via the tail vein, and histopathological changes, survival rate, and the serum levels of liver enzymes were determined. To assess the immune response induced by MSCs, a mass cytometry panel of 43 metal isotope-tagged antibodies was used to characterize the hepatic immune compartment at days 1, 2, 3, and 7 after administration of MSCs or PBS. MSC treatment significantly alleviated CCl4-induced ALI and improved the survival rate. MSC treatment also modulated the hepatic immune system in terms of the distribution of immune-cell subsets and the phenotype of single cells. During the injured phase, MSCs inhibited a systemic response by reducing the numbers of Ly6ClowCD8+ TRM cells, conventional NK cells, and IgM+IgD+ B cells; suppressing the activation of Ly6ChiCD8+ TRM cells; downregulating MHC II and IgM expression in IgM+IgD+ B cells; and increasing the number of immunosuppressive monocyte-derived macrophages. During the recovery phase, MSCs promoted the retention of Ly6ClowCD8+ TRM cells and maintained the immunosuppressive activity of monocyte-derived macrophages. The response to MSC treatment differed between the injured and recovery phases, emphasizing the benefit of dynamic assessment of the immunomodulatory effects of MSCs. We determined the immunomodulatory effects of MSC treatment on the subtype distribution and phenotypes of hepatic immune cells.

25 September 2020 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
BFBing Feng
Bing Feng
JZJiaqi Zhu
Jiaqi Zhu
YXYanping Xu
Yanping Xu
WCWenyi Chen
Wenyi Chen
XSXinyu Sheng
Xinyu Sheng
Hongcui CaoHongcui Cao
Hongcui Cao
Background: Immune system disorders play important roles in acute lung injury (ALI), and mesenchymal stem cell (MSC) treatment can reduce inflammation during ALI. In this study, we compared the changes in lung B cells during MSC treatment.Methods: We investigated the effects of MSCs on lung B cells in a mouse model of lipopolysaccharide (LPS)-induced ALI. MSCs were administered intratracheally 4 h after LPS. As vehicle-treated controls, mice were treated with phosphate-buffered saline (PBS) containing 2% C57BL/6 (PBS group). Histopathological changes, survival rate, inflammatory factor levels, and the number of neutrophils in bronchoalveolar lavage fluid (BALF) were determined. Single-cell RNA sequencing (scRNA-Seq) analysis was performed to evaluate the transcriptional changes in lung B cells between the PBS, LPS, and LPS/MSC groups on days 3 and 7.Results: MSC treatment ameliorated LPS-induced ALI, as indicated by the reductions in mortality, the levels of chemokines and cytokines in BALF, and the severity of lung tissue histopathology in ALI mice. Lung B cells in the PBS group remained undifferentiated and had an inhibitory phenotype. Based on our scRNA-Seq results, the differentially expressed genes (DEGs) in lung B cells in both the PBS group and LPS group were involved in chemotaxis processes and some proinflammatory pathways. MSC treatment inhibited the expression of chemokine genes that were upregulated by LPS and were related to the recruitment of neutrophils into lung tissues. Immunoglobulin-related gene expression was decreased in lung B cells of mice treated with LPS/MSC for 7 days. The DEGs regulated by MSCs were enriched in biological processes, including humoral immune response and apoptotic signaling.Conclusions: Lung B cells played an important role in the effects of treatment of ALI with MSCs. These observations provide new insights into the mechanisms underlying the effects of MSC treatment for ALI.

1 October 2019 in Experimental Cell Research
Verified
Journal Article
Closed access
XSXiaowei Shi
Xiaowei Shi
JLJingqi Liu
Jingqi Liu
DCDeying Chen
Deying Chen
MZMinglei Zhu
Minglei Zhu
JYJiong Yu
Jiong Yu
SZShusen Zheng
Shusen Zheng

28 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
XFXudong Feng
Xudong Feng
JLJingqi Liu
Jingqi Liu
YXYanping Xu
Yanping Xu
JZJiaqi Zhu
Jiaqi Zhu
WCWenyi Chen
Wenyi Chen
Hongcui CaoHongcui Cao
Hongcui Cao